Studying Blood Vessel Response to Exercise in Chronic Kidney Disease
Tests exercise training and several supplements in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Neurovascular Transduction During Exercise in Chronic Kidney Disease
Key facts
- Where
- Atlanta and Decatur, United StatesSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT02947750, who can take part
Where in United States
- Emory University HospitalAtlanta, United StatesTaking people
- Emory University Hospital MidtownAtlanta, United StatesTaking people
- Atlanta VA Health Care SystemDecatur, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Emory University
- Trial code
- NCT02947750
- Record updated
- 18 May 2026
- Original description
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.Read full original descriptionShow less
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.
Inclusion: Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months; Does not exercise regularly (defined as exercising less than 20 minutes twice per week); Willing and able to cooperate with the study protocol; Does not exercise regularly (defined as exercising less than 20 minutes twice per week); Willing and able to cooperate with the study protocol.
Exclusion: ongoing drug or alcohol abuse; symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history; treatment with central alpha agonists (clonidine); current treatment with monoamine oxidase (MAO) inhibitors; any serious systemic disease that might influence survival; uncontrolled hypertension with BP greater than 170/100 mm Hg; severe CKD (eGFR<15 cc/minute); severe anemia with hgb level <9 g/dL; clinical evidence of congestive heart failure or ejection fraction below 35%; diabetic neuropathy; low blood pressure with BP less than 100/50; pregnancy or plans to become pregnant; inability to exercise on a stationary bicycle.